Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins.
Publication
, Journal Article
Salehi, M; Aulinger, BA; D'Alessio, DA
Published in: Endocr Rev
May 2008
Progressive insulin secretory defects, due to either functional abnormalities of the pancreatic beta-cells or a reduction in beta-cell mass, are the cornerstone of type 2 diabetes. Incretin-based drugs hold the potential to improve glucose tolerance by immediate favorable effect on beta-cell physiology as well as by expanding or at least maintaining beta-cell mass, which may delay the progression of the disease. Long-term studies in humans are needed to elaborate on these effects.
Duke Scholars
Published In
Endocr Rev
DOI
ISSN
0163-769X
Publication Date
May 2008
Volume
29
Issue
3
Start / End Page
367 / 379
Location
United States
Related Subject Headings
- Signal Transduction
- Insulin-Secreting Cells
- Incretins
- Humans
- Endocrinology & Metabolism
- Diabetes Mellitus, Type 2
- Animals
- 3215 Reproductive medicine
- 3202 Clinical sciences
- 1114 Paediatrics and Reproductive Medicine
Citation
APA
Chicago
ICMJE
MLA
NLM
Salehi, M., Aulinger, B. A., & D’Alessio, D. A. (2008). Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins. Endocr Rev, 29(3), 367–379. https://doi.org/10.1210/er.2007-0031
Salehi, Marzieh, Benedikt A. Aulinger, and David A. D’Alessio. “Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins.” Endocr Rev 29, no. 3 (May 2008): 367–79. https://doi.org/10.1210/er.2007-0031.
Salehi M, Aulinger BA, D’Alessio DA. Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins. Endocr Rev. 2008 May;29(3):367–79.
Salehi, Marzieh, et al. “Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins.” Endocr Rev, vol. 29, no. 3, May 2008, pp. 367–79. Pubmed, doi:10.1210/er.2007-0031.
Salehi M, Aulinger BA, D’Alessio DA. Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins. Endocr Rev. 2008 May;29(3):367–379.
Published In
Endocr Rev
DOI
ISSN
0163-769X
Publication Date
May 2008
Volume
29
Issue
3
Start / End Page
367 / 379
Location
United States
Related Subject Headings
- Signal Transduction
- Insulin-Secreting Cells
- Incretins
- Humans
- Endocrinology & Metabolism
- Diabetes Mellitus, Type 2
- Animals
- 3215 Reproductive medicine
- 3202 Clinical sciences
- 1114 Paediatrics and Reproductive Medicine